<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01532882</url>
  </required_header>
  <id_info>
    <org_study_id>DIO401-10</org_study_id>
    <nct_id>NCT01532882</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs</brief_title>
  <acronym>EDEN</acronym>
  <official_title>Assessment of the Efficacy and Safety of Diosmin 600mg on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs: a Multicentric, Randomised, Double-blind, Placebo-controlled Trial in Parallel Groups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire Innotech International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire Innotech International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diosmin has a well established use status in improvement of the symptoms of venolymphatic&#xD;
      insufficiency: heavy legs, pain, primo-decubitus restlessness and as complement treatment of&#xD;
      capillary fragility.&#xD;
&#xD;
      Nevertheless, diosmin 600 mg did not benefit from a rigorous clinical study versus placebo,&#xD;
      to establish its efficacy in the pain relief in Chronic Venous Disease (CVD).&#xD;
&#xD;
      The aim of this project led by Dr. Guex is to evaluate the efficacy and safety of diosmin 600&#xD;
      mg - DIOVENOR® on the painful symptoms of CVD of the lower limbs, in a multicentre,&#xD;
      controlled, randomised, double blind, placebo-controlled, parallel-group study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Visual analog Scale score for assessment of the painful venous symptomatology</measure>
    <time_frame>baseline and after 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Painful symptom intensity (daily VAS score) Area Under the Curve</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Daily VAS score for Response rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Daily VAS score for Time to response</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Score of Quality of life questionnaire (SQOR-V)</measure>
    <time_frame>Between baseline and 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Patient's and physician's global satisfaction score</measure>
    <time_frame>At 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (numbers and frequency)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Unusual intakes of analgesic treatments (rate of patients)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Chronic Venous Disease of Lower Limbs</condition>
  <arm_group>
    <arm_group_label>Diosmin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diosmin</intervention_name>
    <description>tablet, 600mg, PO, 1 tab per day during 28 days</description>
    <arm_group_label>Diosmin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, PO, 1 per day during 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient, man or woman, aged 18 and over,&#xD;
&#xD;
          2. Patient presenting a C1s or C2s venous disease grade of the lower limbs&#xD;
&#xD;
          3. Patient presenting a painful venous symptomatology in the lower limbs for at least 15&#xD;
             days.&#xD;
&#xD;
          4. Patient suffering from venous symptomatology in one leg with a painful symptom&#xD;
             intensity higher or equal to 30 mm (VAS= 100mm)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient treated by venotonic treatments or vascular protectants or assimilated dietary&#xD;
             supplements or homeopathic treatments or diuretics within 15 days prior inclusion,&#xD;
&#xD;
          2. Patients who started treatments such as calcium inhibitors, beta-blockers, angiotensin&#xD;
             converting enzyme inhibitors and/or vasodilators and/or vasoconstrictors within 28&#xD;
             days prior inclusion (for patients already taking this type of treatments, dosage&#xD;
             should not have been changed in the 28 days prior inclusion and should not be planned&#xD;
             to change in the course of the study),&#xD;
&#xD;
          3. Patient treated by any analgesic within 7 days prior inclusion,&#xD;
&#xD;
          4. Patient treated by an anti-inflammatory treatment within 7 days prior inclusion,&#xD;
&#xD;
          5. Patient using elastic venous compression&#xD;
&#xD;
          6. Patient presenting permanent oedema,&#xD;
&#xD;
          7. Patients presenting venous skin changes,&#xD;
&#xD;
          8. Patient whose activity in the 4 following weeks (that is to say during the study)&#xD;
             would be different from his/her usual activities (before the study),&#xD;
&#xD;
          9. Patient suffering from a pathology generating other pains than venous pains in the&#xD;
             lower limbs,&#xD;
&#xD;
         10. Patient with a history of lower limbs trauma responsible for sequel pains,&#xD;
&#xD;
         11. Patient with a known deep venous reflux,&#xD;
&#xD;
         12. Patient with a history of venous thromboses or thrombo-embolic diseases within the&#xD;
             last 6 months before inclusion,&#xD;
&#xD;
         13. Patient treated with analgesics or anti-inflammatory treatments used as analgesics&#xD;
             within 4 weeks prior inclusion&#xD;
&#xD;
         14. Patient having a known hypersensitivity to diosmin or one of the excipients&#xD;
&#xD;
         15. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption ),&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Jérôme GUEX, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Dr Jean-Jérôme GUEX</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <last_update_submitted>April 26, 2013</last_update_submitted>
  <last_update_submitted_qc>April 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

